Clinical Read2026-06-08

Trodelvy (sacituzumab govitecan-hziy) + KEYTRUDA (pembrolizumab) - (EVOKE-03)

Gilead Sciences Inc.GILD
Indication
Non-small cell lung cancer (NSCLC)
Stage
phase3
Event
Phase 3